Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 456

1.

Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.

Heinrich EL, Lee W, Lu J, Lowy AM, Kim J.

J Transl Med. 2012 Apr 2;10:68. doi: 10.1186/1479-5876-10-68.

2.

CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7.

Coggins NL, Trakimas D, Chang SL, Ehrlich A, Ray P, Luker KE, Linderman JJ, Luker GD.

PLoS One. 2014 Jun 4;9(6):e98328. doi: 10.1371/journal.pone.0098328. eCollection 2014.

3.

Imaging ligand-dependent activation of CXCR7.

Luker KE, Gupta M, Steele JM, Foerster BR, Luker GD.

Neoplasia. 2009 Oct;11(10):1022-35.

4.

Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.

Ehrlich A, Ray P, Luker KE, Lolis EJ, Luker GD.

Biochem Pharmacol. 2013 Nov 1;86(9):1263-71. doi: 10.1016/j.bcp.2013.08.019. Epub 2013 Aug 22.

5.

CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration.

Décaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P.

J Biol Chem. 2011 Sep 16;286(37):32188-97. doi: 10.1074/jbc.M111.277038. Epub 2011 Jul 5.

6.

The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.

Gravel S, Malouf C, Boulais PE, Berchiche YA, Oishi S, Fujii N, Leduc R, Sinnett D, Heveker N.

J Biol Chem. 2010 Dec 3;285(49):37939-43. doi: 10.1074/jbc.C110.147470. Epub 2010 Oct 18.

7.

Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways.

Shen X, Artinyan A, Jackson D, Thomas RM, Lowy AM, Kim J.

Pancreas. 2010 Jan;39(1):81-7. doi: 10.1097/MPA.0b013e3181bb2ab7.

PMID:
19820417
8.

Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands.

Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD.

Oncogene. 2010 Aug 12;29(32):4599-610. doi: 10.1038/onc.2010.212. Epub 2010 Jun 7.

9.

The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells.

Odemis V, Lipfert J, Kraft R, Hajek P, Abraham G, Hattermann K, Mentlein R, Engele J.

Glia. 2012 Mar;60(3):372-81. doi: 10.1002/glia.22271. Epub 2011 Nov 14.

PMID:
22083878
10.

The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.

Shakir M, Tang D, Zeh HJ, Tang SW, Anderson CJ, Bahary N, Lotze MT.

Pancreas. 2015 May;44(4):528-34. doi: 10.1097/MPA.0000000000000298. Review.

PMID:
25872129
11.

CXCR7 participates in CXCL12-induced CD34+ cell cycling through β-arrestin-dependent Akt activation.

Torossian F, Anginot A, Chabanon A, Clay D, Guerton B, Desterke C, Boutin L, Marullo S, Scott MG, Lataillade JJ, Le Bousse-Kerdilès MC.

Blood. 2014 Jan 9;123(2):191-202. doi: 10.1182/blood-2013-05-500496. Epub 2013 Nov 25.

12.

Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer.

Zhu X, Bai Q, Lu Y, Lu Y, Zhu L, Zhou X, Wu L.

Int J Oncol. 2016 Jun;48(6):2321-9. doi: 10.3892/ijo.2016.3485. Epub 2016 Apr 12.

13.

CXCR7 mediates SDF1-induced melanocyte migration.

Lee E, Han J, Kim K, Choi H, Cho EG, Lee TR.

Pigment Cell Melanoma Res. 2013 Jan;26(1):58-66. doi: 10.1111/pcmr.12024. Epub 2012 Oct 26.

PMID:
22978759
14.

Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.

Qiao N, Wang L, Wang T, Li H.

Tumour Biol. 2016 Jun;37(6):8169-79. doi: 10.1007/s13277-015-4686-2. Epub 2015 Dec 29.

PMID:
26715277
15.

Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma.

Liberman J, Sartelet H, Flahaut M, Mühlethaler-Mottet A, Coulon A, Nyalendo C, Vassal G, Joseph JM, Gross N.

PLoS One. 2012;7(8):e43665. doi: 10.1371/journal.pone.0043665. Epub 2012 Aug 20.

16.

CXCR7 mediated Giα independent activation of ERK and Akt promotes cell survival and chemotaxis in T cells.

Kumar R, Tripathi V, Ahmad M, Nath N, Mir RA, Chauhan SS, Luthra K.

Cell Immunol. 2012;272(2):230-41. doi: 10.1016/j.cellimm.2011.09.015. Epub 2011 Oct 20. Erratum in: Cell Immunol. 2014 Aug;290(2):251.

PMID:
22070874
17.

Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.

Boudot A, Kerdivel G, Habauzit D, Eeckhoute J, Le Dily F, Flouriot G, Samson M, Pakdel F.

PLoS One. 2011;6(6):e20898. doi: 10.1371/journal.pone.0020898. Epub 2011 Jun 10.

18.

The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation.

Salazar N, Muñoz D, Kallifatidis G, Singh RK, Jordà M, Lokeshwar BL.

Mol Cancer. 2014 Aug 28;13:198. doi: 10.1186/1476-4598-13-198.

19.

Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.

Hsiao JJ, Ng BH, Smits MM, Wang J, Jasavala RJ, Martinez HD, Lee J, Alston JJ, Misonou H, Trimmer JS, Wright ME.

BMC Cancer. 2015 Mar 31;15:204. doi: 10.1186/s12885-015-1201-5.

20.

The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.

Hattermann K, Held-Feindt J, Lucius R, Müerköster SS, Penfold ME, Schall TJ, Mentlein R.

Cancer Res. 2010 Apr 15;70(8):3299-308. doi: 10.1158/0008-5472.CAN-09-3642. Epub 2010 Apr 13.

Supplemental Content

Support Center